Impact News +++ Beyond Oil Continues its Commercial Expansion in the United States Market (GlobeNewswire EN) +++ SYSCO Aktie +3,69%

CURIS Aktie

>CURIS Aktienkurs

0.73 EUR +0.7% (Tradegate)

Ask: 0.74 EUR / 5375 Stück

Bid: 0.71 EUR / 5634 Stück

Tagesumsatz: 36320 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CURIS Aktie über LYNX handeln

Intraday

1 Jahr

>CURIS Performance

1 Woche: -17,5%

1 Monat: -37,6%

3 Monate: -47,9%

6 Monate: -50,0%

1 Jahr: -78,4%

laufendes Jahr: -17,5%

>CURIS Aktie

Name:

CURIS INC. DL -,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US2312693094 / A3ETJD

Symbol/ Ticker:

CUS0 (Frankfurt) / CRIS (NASDAQ)

Kürzel:

FRA:CUS0, ETR:CUS0, CUS0:GR, NASDAQ:CRIS

Index:

Webseite:

https://www.curis.com/

Profil:

Curis Inc. is a biotechnology company focused on t..
>Volltext..

Marktkapitalisierung:

10.89 Mio. EUR

Unternehmenswert:

29.3 Mio. EUR

Umsatz:

9.97 Mio. EUR

EBITDA:

-29.23 Mio. EUR

Nettogewinn:

-31.27 Mio. EUR

Gewinn je Aktie:

-3.15 EUR

Schulden:

26.17 Mio. EUR

Liquide Mittel:

7.74 Mio. EUR

Operativer Cashflow:

-25.74 Mio. EUR

Bargeldquote:

0.45

Umsatzwachstum:

7.75%

Gewinnwachstum:

23.74%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CURIS

Letzte Datenerhebung:

08.01.26

>CURIS Kennzahlen

Aktien/ Unternehmen:

Aktien: 12.93 Mio. St.

Frei handelbar: 91.9%

Leerverk. Aktien: 0.83%

Rückkaufquote: -208.21%

Mitarbeiter: 34

Umsatz/Mitarb.: 0.27 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 1284.57%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.46

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 98.19%

Gewinnmarge: -313.79%

Operative Marge: -294.64%

Managementeffizenz:

Gesamtkaprendite: -104.28%

Eigenkaprendite: -

>CURIS Peer Group

Es sind 595 Aktien bekannt.

>CURIS Chart & Kurs - NASDAQ

>CURIS News

07.01.26 - 15:42	Curis prices private placement of $80.8M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.01.26 - 15:24	Privatplatzierung über 80,8 Mio. US-Dollar beflügelt Curis-Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

07.01.26 - 14:48	Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds (PR Newswire)
	LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement......

14.11.25 - 15:30	Curis to Present at Upcoming 30th Annual SNO Meeting (PR Newswire)
	LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in......

07.11.25 - 20:00	Curis anticipates initial CLL proof-of-concept study data at ASH 2026 while advancing PCNSL and AML programs (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 23:03	Curis GAAP EPS of -$0.49 beats by $0.09, revenue of $3.18M beats by $0.32M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 22:03	Curis Provides Third Quarter 2025 Business Update (PR Newswire)
	Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today......

30.10.25 - 21:03	Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025 (PR Newswire)
	LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and......

03.10.25 - 22:03	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	LEXINGTON, Mass., Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of......

02.09.25 - 16:45	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
	LEXINGTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis,......

06.08.25 - 00:36	Curis (CRIS) Q2 Loss Narrows 66% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.25 - 17:30	Curis targets enrolling 30–40 additional patients for NDA and EMA submissions as emavusertib studies advance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.25 - 14:18	Curis GAAP EPS of -$0.68 beats by $0.68, revenue of $2.7M beats by $0.06M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.25 - 14:03	Curis Provides Second Quarter 2025 Business Update (PR Newswire)
	Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported......

04.08.25 - 17:30	Curis Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 14:33	Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025 (PR Newswire)
	LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and......

02.07.25 - 14:36	Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement (PR Newswire)
	LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a......

07.05.25 - 00:18	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement......

06.05.25 - 20:45	Curis highlights progress in lymphoma and AML trials with expanded patient enrollment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.25 - 15:33	Shawn "JAY-Z" Carter Files Amended Lawsuit in Alabama To Include Lawyer Antigone Curis As Co-Conspirator and To Reveal Tony Buzbee Edited Wikipedia Pages To Damage Carter & Roc Nation′s Reputations (PR Newswire)
	NEW YORK, May 6, 2025 /PRNewswire/ -- Today, Shawn "JAY-Z" Carter filed an amended lawsuit in Alabama that revealed that lawyer Tony Buzbee directed his employees to negatively edit Carter and his company Roc Nation's Wikipedia pages to damage their reputations. The complaint explains......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Eine Frau, die ein Schöngeist ist, ist die Geißel ihres Mannes, ihrer Kinder, ihrer Freunde, ihres Gesindes und der ganzen Welt. - Jean-Jacques Rousseau

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram